Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program

Journal of Clinical Oncology

Volumn 16, Issue 8, 1998, Pages 2825-2833

  McLaughlin, Peter ^a   Grillo López, Antonio J ^b   Link, Brian K ^b   Levy, Ronald ^b   Czuczman, Myron S ^b   Williams, Michael E ^b   Heyman, Meyer R ^b   Bence Bruckler, Isabelle ^b   White, Christine A ^b   Cabanillas, Fernando ^b   Jain, Vinay ^b   Ho, Anthony D ^b   Lister, John ^b   Wey, Ken ^b   Shen, David ^b   Dallaire, Brian K ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C2B8; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0345337254     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.8.2825     Document Type: Article

References (38)

1. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656-2675, 1995
2. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
3. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
4. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980
5. Anderson KC, Bates MP, Slaughenhoupt BL, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984
6. Zhou L-J, Tedder TF: CD20 Workshop Panel Report, in Schlossman SF, Boumsell L, Gilks W, et al (eds): Leucocyte Typing V. White Cell Differentiation Antigens. Oxford, United Kingdom, Oxford University, 1995, pp 511-514
7. Einfeld DA, Brown JP, Valentine MA, et al: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711-717, 1988
8. Tedder TF, Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today 15:450-454, 1994
9. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
10. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993
11. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
12. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
13. Grossbard ML, Press OW, Appelbaum FR, et al: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878, 1992
14. Liu AY, Robinson RR, Murray ED. et al: Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 139:3521-3526, 1987
15. LoBuglio AF, Wheeler RH, Trang J, et al: Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 86:4220-4224, 1989
16. Mueller BM, Romerdahl CA, Gillies SD, et al: Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386, 1990
17. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
18. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466, 1994
19. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
20. Gribben JG, Neuberg D, Barber M, et al: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800-3807, 1994
21. Horning S, Cheson B, Peterson B, et al: Response criteria and quality assurance of response in the evaluation of new therapies for patients with low-grade lymphoma. Proc Am Soc Clin Oncol 16:18a, 1997 (abstr)
22. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. SAS: SAS/STAT User's Guide, Version 6. Cary, NC, SAS Institute, 1990
24. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
25. Pott-Hoeck C, Hiddemann W: Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 6:421-433, 1995
26. Piro LD: Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Semin Hematol 33:34-39. 1996(suppl 1)
27. McLaughlin P, Robertson LE, Keating JM: Fludarabine phosphate in lymphoma: an important new therapeutic agent, in Cabanillas F, Rodriguez MA (eds): Advances in Lymphoma Research. Boston, MA, Kluwer Academic, 1996, pp 3-14
28. Nadler LM, Stashenko P, Hardy R, et al: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147-3154, 1980
29. Ritz J, Pesando JM, Sallan SE, et al: Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141-152, 1981
30. Foon KA, Schroff RW, Bunn PA, et al: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085-1093, 1984
31. Dillman RO, Shawler DL, Dillman JB, et al: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881-891, 1984
32. Czuczman MS, Grillo-Lopez AJ, Jonas C, et al: Chemoimmunotherapy of low-grade lymphoma with the anti-CD20 antibody IDEC-C2B8 in combination with CHOP chemotherapy. Cancer Invest 14:59-61, 1996 (suppl 1)
33. Clendeninn NJ, Nethersell ABW, Scon JE, et al: Phase I/II trials of CAMPATH-1H, a humanized anti-lymphocyte monoclonal antibody, in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 80:158a 1992 (suppl 1, abstr)
34. Poynton CH, Mort D, Maughan TS: Adverse reactions to Campath-1H monoclonal antibody. Lancet 341:1037, 1993 (letter)
35. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259-263, 1992
36. Lopez-Guillermo A, Lee MS, Pugh W, et al: The molecular breakpoint site of bcl-2 gene has prognostic importance in indolent follicular lymphoma. Blood 88:293a, 1996 (suppl 1, abstr)
37. Demidem A, Hanna N, Hariharan H, et al: Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP. VP-16 and toxins. FASEB J 9:A206, 1995 (abstr)
38. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferation activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 88:637a, 1996 (suppl 1, abstr)